A physiologically based pharmacokinetic model for Valproic acid in adults and children

European Journal of Pharmaceutical Sciences

Volumn 63, Issue , 2014, Pages 45-52

  Ogungbenro, Kayode ^a   Aarons, Leon ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Dravet syndrome; Epilepsy; Modelling; PBPK; Pharmacokinetics; Valproic acid

Indexed keywords

CLOBAZAM; STIRIPENTOL; VALPROIC ACID;

ADULT; ARTICLE; BLOOD; BRAIN; CHILD; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG TISSUE LEVEL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTESTINE; INTESTINE CELL; KIDNEY; LIVER; MODEL; MUSCLE; PHARMACOLOGICAL PARAMETERS; PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SEVERE MYOCLONIC EPILEPSY IN INFANCY; SIMULATION; SPLEEN; ADOLESCENT; BIOLOGICAL MODEL; TISSUE DISTRIBUTION; YOUNG ADULT;

ADOLESCENT; ADULT; HUMANS; MODELS, BIOLOGICAL; TISSUE DISTRIBUTION; VALPROIC ACID; YOUNG ADULT;

EID: 84904893896     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2014.06.023     Document Type: Article

References (49)

1. U.A. Argikar, and R.P. Remmel Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP- glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10 Drug Metab. Dispos. 37 1 2009 229 236
2. J.S. Barrett, O. Della Casa Alberighi, S. Laer, and B. Meibohm Physiologically based pharmacokinetic (PBPK) modeling in children Clin. Pharmacol. Ther. 92 1 2012 40 49
3. M. Bialer, Z. Hussein, I. Raz, O. Abramsky, Y. Herishanu, and F. Pachys Pharmacokinetics of valproic acid in volunteers after a single dose study Biopharm. Drug Dispos. 6 1 1985 33 42 (Pubitemid 15100656)
4. I.B. Bondareva, R.W. Jelliffe, A.V. Sokolov, and I.F. Tischenkova Nonparametric population modeling of valproate pharmacokinetics in epileptic patients using routine serum monitoring data: implications for dosage J. Clin. Pharm. Ther. 29 2 2004 105 120 (Pubitemid 38482475)
5. S.M. Bryson, N. Verma, P.J. Scott, and P.C. Rubin Pharmacokinetics of valproic acid in young and elderly subjects Br. J. Clin. Pharmacol. 16 1 1983 104 105 (Pubitemid 13061378)
6. K. Chiba, T. Suganuma, T. Ishizaki, T. Iriki, Y. Shirai, H. Naitoh, and M. Hori Comparison of steady-state pharmacokinetics of valproic acid in children between monotherapy and multiple antiepileptic drug treatment J. Pediatr. 106 4 1985 653 658 (Pubitemid 15080565)
7. C. Chiron, M.C. Marchand, A. Tran, E. Rey, P. d'Athis, J. Vincent, O. Dulac, and G. Pons Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial STICLO study group. Lancet 356 9242 2000 1638 1642
8. J.C. Cloyd, S. Dutta, G. Cao, J.K. Walch, S.D. Collins, G.R. Granneman, and G. Depacon Study Valproate unbound fraction and distribution volume following rapid infusions in patients with epilepsy Epilepsy Res. 53 1-2 2003 19 27 (Pubitemid 36170167)
9. J.C. Cloyd, J.H. Fischer, R.L. Kriel, and D.M. Kraus Valproic acid pharmacokinetics in children. IV. Effects of age and antiepileptic drugs on protein binding and intrinsic clearance Clin. Pharm. Ther. 53 1 1993 22 29 (Pubitemid 23036684)
10. D. DuBois, and E.F. DuBois A formula to estimate the approximate surface area if height and weight be known Arch. Int. Med. 17 6-2 1916 863 871
11. S. Dutta, and R.C. Reed Distinct absorption characteristics of oral formulations of valproic acid/divalproex available in the United States Epilepsy Res. 73 3 2007 275 283
12. A.N. Edginton Knowledge-driven approaches for the guidance of first-in-children dosing Pediatr. Anesthesia 21 3 2011 206 213
13. A.N. Edginton, W. Schmitt, B. Voith, and S. Willmann A mechanistic approach for the scaling of clearance in children Clin. Pharmacokinet. 45 7 2006 683 704 (Pubitemid 43990570)
14. K. Hall, N. Otten, B. Johnston, J. Irvine-Meek, M. Leroux, and S. Seshia A multivariable analysis of factors governing the steady-state pharmacokinetics of valproic acid in 52 young epileptics J. Clin. Pharmacol. 25 4 1985 261 268 (Pubitemid 15091099)
15. G.B. Haycock, G.J. Schwartz, and D.H. Wisotsky Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults J. Pediatr. 93 1 1978 62 66 (Pubitemid 8351870)
16. P.C. Ho, F.S. Abbott, U.M. Zanger, and T.K.H. Chang Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes Pharmacogenomics J. 3 6 2003 335 342 (Pubitemid 38072171)
17. D.L. Hurst Epidemiology of severe myoclonic epilepsy of infancy Epilepsia 31 4 1990 397 400 (Pubitemid 20226666)
18. F. Ichimura, Y. Deguchi, K. Yokogawa, and T. Yamana Physiologically based pharmacokinetics of valproic acid in rabbits Int. J. Pharm. 27 1 1985 45 60 (Pubitemid 15246921)
19. M. Jamei, D. Turner, J. Yang, S. Neuhoff, S. Polak, A. Rostami-Hodjegan, and G. Tucker Population-based mechanistic prediction of oral drug absorption AAPS J. 11 2 2009 225 237
20. X.L. Jiang, P. Zhao, J.S. Barrett, L.J. Lesko, and S. Schmidt Application of physiologically based pharmacokinetic modeling to predict acetaminophen metabolism and pharmacokinetics in children CPT: Pharmacomet. Syst. Pharmacol. 2 2013 e80
21. T.N. Johnson, A. Rostami-Hodjegan, and G.T. Tucker Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children Clin. Pharmacokinet. 45 9 2006 931 956 (Pubitemid 44299829)
22. U. Klotz Pharmacokinetic studies with Valproic acid in man Arzneimittel-Forsch 27 5 1977 1085 1088 (Pubitemid 8097057)
23. U. Klotz, and K.H. Antonin Pharmacokinetics and bioavailability of sodium valproate Clin. Pharmacol. Ther. 21 6 1977 736 743 (Pubitemid 8131717)
24. R. Leong, M.L.T. Vieira, P. Zhao, Y. Mulugeta, C.S. Lee, S.M. Huang, and G.J. Burckart Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials Clin. Pharmacol. Ther. 91 5 2012 926 931
25. R.H. Levy, A.W. Rettenmeier, G.D. Anderson, A.J. Wilensky, P.N. Friel, T.A. Baillie, A. Acheampong, J. Tor, M. Guyot, and P. Loiseau Effects of polytherapy with phenytoin, carbamazepine, and stiripentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid Clin. Pharmacol. Ther. 48 3 1990 225 235 (Pubitemid 20323648)
26. W. Loscher Serum-protein binding and pharmacokinetics of Valproate in man, dog, rat and mouse J. Pharmacol. Exp. Ther. 204 2 1978 255 261 (Pubitemid 8290127)
27. B. Lundberg, A. Nergardh, and L.O. Boreus Plasma concentrations of Valproate during maintenance therapy in epileptic children J. Neurol. 228 2 1982 133 141 (Pubitemid 13240892)
28. A.R. Maharaj, J.S. Barrett, and A.N. Edginton A workflow example of PBPK modeling to support pediatric research and development: case study with lorazepam AAPS J. 15 2 2013 455 464
29. D.B. McLaughlin, J.A. Andrews, W.D. Hooper, G.R. Cannell, M.J. Eadie, and R.G. Dickinson Apparent autoinduction of valproate beta-oxidation in humans Br. J. Clin. Pharmacol. 49 5 2000 409 415 (Pubitemid 30229443)
30. R.P. Morse Dravet syndrome: inroads into understanding epileptic encephalopathies J. Pediatr. 158 3 2011 354 359
31. V. Nitsche, and H. Mascher The pharmacokinetics of valproic acid after oral and parenteral administration in healthy-volunteers Epilepsia 23 2 1982 153 162 (Pubitemid 12107680)
32. E. Perucca, G. Gatti, G.M. Frigo, and A. Crema Pharmacokinetics of Valproic acid after oral and intravenous administration Br. J. Clin. Pharmacol. 5 4 1978 313 318 (Pubitemid 8297733)
33. E. Perucca, G. Gatti, G.M. Frigo, A. Crema, S. Calzetti, and D. Visintini Disposition of sodium Valproate in epileptic patients Br. J. Clin. Pharmacol. 5 6 1978 495 499 (Pubitemid 8348589)
34. T. Rodgers, D. Leahy, and M. Rowland Physiologically based pharmacokinetic modeling 1: Predicting the tissue distribution of moderate-to-strong bases J. Pharm. Sci. 94 6 2005 1259 1276 (Pubitemid 40904190)
35. T. Rodgers, and M. Rowland Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions J. Pharm. Sci. 95 6 2006 1238 1257 (Pubitemid 43874439)
36. Yeo K. Rowland, M. Jamei, J. Yang, G.T. Tucker, and A. Rostami-Hodjegan Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - the effect of diltiazem on the time-course of exposure to triazolam Eur. J. Pharm. Sci.: Off. J. Eur. Fed. Pharma. Sci. 39 5 2010 298 309
37. A.J.M. Sadeque, M.B. Fisher, K.R. Korzekwa, F.J. Gonzalez, and A.E. Rettie Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid J. Pharmacol. Exp. Ther. 283 2 1997 698 703 (Pubitemid 27514629)
38. F. Salem, T.N. Johnson, Z.E. Barter, J.S. Leeder, and A. Rostami-Hodjegan Age related changes in fractional elimination pathways for drugs: assessing the impact of variable ontogeny on metabolic drug-drug interactions J. Clin. Pharmacol. 53 8 2013 857 865
39. R.D. Scheyer, J.A. Cramer, B.R. Toftness, J.M. Hochholzer, and R.H. Mattson Invivo determination of Valproate binding constants during sole and multidrug therapy Ther. Drug Monit. 12 2 1990 117 123 (Pubitemid 20078589)
40. M.G. Soars, B. Burchell, and R.J. Riley In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance J. Pharmacol. Exp. Ther. 301 1 2002 382 390 (Pubitemid 34250317)
41. Y. Suzuki, H. Itoh, T. Abe, F. Nishimura, Y. Sato, and M. Takeyama No effect of co-administered antiepileptic drugs on in-vivo protein binding parameters of valproic acid in patients with epilepsy J. Pharm. Pharmacol. 63 7 2011 976 981
42. S. Ueshima, T. Aiba, N. Ishikawa, T. Sato, H. Kawasaki, Y. Kurosaki, Y. Ohtsuka, and T. Sendo Poor applicability of estimation method for adults to calculate unbound serum concentrations of valproic acid in epileptic neonates and infants J. Clin. Pharm. Ther. 34 4 2009 415 422
43. S. Ueshima, T. Aiba, T. Sato, H. Matsunaga, Y. Kurosaki, Y. Ohtsuka, and T. Sendo Empirical approach for improved estimation of unbound serum concentrations of Valproic acid in epileptic infants by considering their physical development Biol. Pharm. Bull. 34 1 2011 108 113
44. J. Valentin Basic anatomical and physiological data for use in radiological protection: reference values: ICRP publication 89 Ann. ICRP 32 3-4 2002 1 277
45. A. Visudtibhan, K. Bhudhisawadi, J. Vaewpanich, S. Chulavatnatol, and S. Kaojareon Pharmacokinetics and clinical application of intravenous valproate in Thai epileptic children Brain Dev. 33 3 2011 189 194
46. G.B. West, J.H. Brown, and B.J. Enquist The fourth dimension of life: fractal geometry and allometric scaling of organisms Science 284 5420 1999 1677 1679 (Pubitemid 29291379)
47. G.B. West, J.H. Brown, and B.J. Enquist A general model for the origin of allometric scaling laws in biology Science 276 5309 1997 122 126 (Pubitemid 27161259)
48. J.H. Williams, B. Jayaraman, K.J. Swoboda, and J.S. Barrett Population pharmacokinetics of Valproic acid in pediatric patients with epilepsy: considerations for dosing spinal muscular atrophy patients J. Clin. Pharmacol. 52 11 2012 1676 1688
49. G. Zaccara, A. Messori, and F. Moroni Clinical pharmacokinetics of valproic acid-1988 Clin. Pharmacokinet. 15 6 1988 367 389